<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911211-0028</DOCNO><DOCID>911211-0028.</DOCID><HL>   Technology:   Chiron Cleared to Acquire   Cetus Corp. in Stock Swap</HL><DATE>12/11/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B3</SO><CO>   CHIR CTUS Z.ROC</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>BIOTECHNOLOGY (BTC)DRUG MANUFACTURERS (DRG)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)TENDER OFFERS, MERGERS, ACQUISITIONS (TNM)</IN><NS>ACQUISITIONS andamp; MERGERS, TAKEOVERS, BOARD BATTLES (TNM)</NS><RE>CALIFORNIA (CA)EUROPE (EU)NORTH AMERICA (NME)PACIFIC RIM (PRM)SWITZERLAND (SZ)UNITED STATES (US)WESTERN EUROPE (WEU)</RE><LP>   EMERYVILLE, Calif. -- Chiron Corp. won the necessaryshareholder approvals to acquire Cetus Corp. tomorrow in astock swap valued at about $660 million, the twobiotechnology companies said.   Cetus said its holders approved the sale of its polymerasechain reaction -- or PCR -- technology for $300 million pluspossible future royalties to Hoffman-La Roche Inc., a unit ofRoche Holding Ltd. of Basel, Switzerland. PCR is the use ofgenetic material to identify everything from criminalsuspects to the microbes that cause disease.</LP><TEXT>   Chiron holders approved the merger transaction, involvingthe issuance of about 10 million new Chiron shares,increasing the company's shares outstanding to about 30million. Chiron's shares were quoted at $64 each, unchanged,in over-the-counter trading yesterday.   After the merger, the company will have about 1,500employees. Chiron said yesterday it expects to announce a 10%work-force reduction in January. Cetus already has beentrimming its payroll.   The combined company will focus on four major markets:diagnostics, vaccines, opthalmics, and therapeutic productsprimarily for cancer. Chiron has a major program to developvaccines against AIDS, herpes and hepatitis, while Cetus haspioneered the development and testing of the human proteininterleukin-2 as an experimental treatment for kidney cancer.</TEXT></DOC>